8-K: TransCode Therapeutics Reports 2023 Results and Provides Business Update, Advances Lead Candidate to Phase 1 Trial

TransCode Therapeutics announced its 2023 financial results, highlighted by advancing its lead therapeutic candidate, TTX-MC138, into a Phase 1 clinical trial and securing over $25 million in equity financing.

Summary

• TransCode Therapeutics reported its financial results for 2023, noting a productive year with the advancement of their lead therapeutic candidate, TTX-MC138, into clinical trials.
• The company raised over $25 million through equity financings despite challenging financial markets.
• TransCode streamlined operations and entered into two strategic collaborations to explore the value of their TTX platform.
• Preliminary clinical results from a Phase 0 trial with radiolabeled TTX-MC138 showed delivery to metastatic lesions.
• The company plans to initiate a Phase 1 clinical trial for TTX-MC138 in mid-2024, pending FDA authorization.
• Cash reserves were $2.8 million as of December 31, 2023, compared to $4.97 million the previous year.
• Research and development expenses increased to $12.3 million in 2023 from $10.2 million in 2022.
• General and administrative expenses decreased to $7.2 million in 2023 from $8.4 million in 2022.
• The operating loss was $19.4 million in 2023, compared to $18.6 million in 2022.
• The company expects its cash, along with $6.2 million from a January 2024 offering, to fund operations into late third or early fourth quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in clinical trials and strategic partnerships, but also acknowledges financial challenges and the need for further funding. The sentiment is cautiously optimistic.

Positives

• The company successfully advanced its lead therapeutic candidate, TTX-MC138, into clinical trials.
• TransCode secured significant funding of over $25 million through equity financings.
• Strategic collaborations were established to broaden the application of their technology.
• Positive preclinical results were reported for multiple therapeutic candidates.
• The company received a second Orphan Drug Designation from the FDA.
• The company regained compliance with Nasdaq's stockholders equity requirement.

Negatives

• The company's cash reserves decreased from $4.97 million to $2.8 million year-over-year.
• The operating loss increased from $18.6 million to $19.4 million year-over-year.
• The company's cash runway is only expected to last until late third or early fourth quarter of 2024.

Risks

• The company's future success is dependent on the outcome of clinical trials.
• There are risks associated with obtaining and maintaining regulatory approvals.
• The company faces competition from other companies developing similar products.
• TransCode needs to secure additional funding to support its business activities.
• The company is dependent on third parties for various aspects of its operations.
• Geopolitical events and pandemics could impact the company's operations.

Future Outlook

TransCode expects its current cash and recent capital raise to fund operations into late third or early fourth quarter of 2024, and plans to initiate a Phase 1 clinical trial for TTX-MC138 in mid-2024, while also continuing preclinical studies and strategic partnerships.

Management Comments

• We believe 2023 was extremely productive and pivotal for TransCode.
• We are proud to have advanced our lead therapeutic candidate, TTX-MC138, into the clinic as a first-in-class drug candidate against metastatic cancer.
• The year was highlighted by preliminary clinical results from our Phase 0 clinical trial with radiolabeled TTX-MC138.
• Despite very challenging financial markets, we raised over $25 million in equity financings, streamlined our operations for higher efficiency, and signed two strategic collaborations.
• We now look forward to our Phase 1 clinical trial of TTX-MC138 which, subject to FDA authorization, is planned to begin in mid-2024.

Industry Context

This announcement reflects the ongoing efforts in the RNA therapeutics space to develop novel treatments for cancer, with a focus on targeted delivery and overcoming the challenges of RNA delivery. The company's focus on metastatic disease and its proprietary TTX nanoparticle platform aligns with current industry trends.

Comparison to Industry Standards

• TransCode's focus on RNA therapeutics for cancer aligns with companies like Moderna and BioNTech, though these companies are much larger and have more advanced pipelines.
• The company's approach to targeting microRNA-10b is unique, differentiating it from companies focusing on more established targets.
• The $25 million capital raise is relatively small compared to the funding rounds of larger biotech companies, but is significant for a company of TransCode's size.
• The company's cash runway into late third or early fourth quarter of 2024 is typical for early-stage biotech companies, which often require frequent capital raises.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the clinical progress and strategic partnerships, but also concerned about the company's cash position and need for further funding.
• Employees may be impacted by the company's focus on streamlining operations and reducing cash burn.
• Customers and suppliers may be impacted by the company's development programs and strategic partnerships.
• Creditors may be impacted by the company's financial condition and need for additional funding.

Next Steps

• Initiate a Phase 1 clinical trial with TTX-MC138 in patients with advanced solid tumors.
• Report preliminary results from the planned Phase 1 trial later this year.
• Publish preclinical results supporting TTX-MC138 in glioblastoma and pancreatic cancer, TTX-siPDL1 in pancreatic cancer, and TTX-RIGA in melanoma.
• Continue preclinical studies for therapeutic candidates TTX-mRNA and TTX-CRISPR.
• Advance existing strategic partnerships and sign others.
• Further develop an exploratory test for miRNA-10b.
• Initiate CMC development to support future IND-enabling studies with TTX-siPDL1 or TTX-RIGA candidates, if capital resources permit.

Key Dates

Keywords

RNA therapeutics, oncology, metastatic cancer, TTX-MC138, clinical trials, equity financing, preclinical results, Orphan Drug Designation, strategic collaborations, cash runway